APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Solid Tumors Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Solid Tumors Drugs Industry Research Report 2026

Report ID 174036790520 December 2025135 pages

Choose your research edition.

Industry ResearchSolid Tumors Drugs Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal Solid Tumors Drugs Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Solid Tumors Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Solid Tumors Drugs Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Solid Tumors Drugs Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Solid Tumors Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Solid Tumors Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Solid Tumors Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Solid Tumors Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Solid Tumors Drugs include Sanofi, Johnson & Johnson, Novartis, Merck, Eli Lilly, Pfizer, GSK, Bayer and AbbVie, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Solid Tumors Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Solid Tumors Drugs Market by Company

Sanofi

Johnson & Johnson

Novartis

Merck

Eli Lilly

Pfizer

GSK

Bayer

AbbVie

AstraZeneca

Hoffmann-La Roche

Daiichi Sankyo

Celgene

Boston Biomedical

Boehringer Ingelheim

BMS

Biogen

Solid Tumors Drugs Segment by Type

Small Molecules

Biologics

Solid Tumors Drugs Segment by Application

Academic and Research Institutes

Hospitals

Clinics

Others

Solid Tumors Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Solid Tumors Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Solid Tumors Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Solid Tumors Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Solid Tumors Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Solid Tumors Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Solid Tumors Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Solid Tumors Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Solid Tumors Drugs Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Solid Tumors Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Solid Tumors Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Solid Tumors Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Solid Tumors Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Solid Tumors Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Solid Tumors Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Solid Tumors Drugs, Product Type & Application Table 14. Global Solid Tumors Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Solid Tumors Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Sanofi Company Information Table 19. Sanofi Business Overview Table 20. Sanofi Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Sanofi Solid Tumors Drugs Product Portfolio Table 22. Sanofi Recent Developments Table 23. Johnson & Johnson Company Information Table 24. Johnson & Johnson Business Overview Table 25. Johnson & Johnson Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Johnson & Johnson Solid Tumors Drugs Product Portfolio Table 27. Johnson & Johnson Recent Developments Table 28. Novartis Company Information Table 29. Novartis Business Overview Table 30. Novartis Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Novartis Solid Tumors Drugs Product Portfolio Table 32. Novartis Recent Developments Table 33. Merck Company Information Table 34. Merck Business Overview Table 35. Merck Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Merck Solid Tumors Drugs Product Portfolio Table 37. Merck Recent Developments Table 38. Eli Lilly Company Information Table 39. Eli Lilly Business Overview Table 40. Eli Lilly Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Eli Lilly Solid Tumors Drugs Product Portfolio Table 42. Eli Lilly Recent Developments Table 43. Pfizer Company Information Table 44. Pfizer Business Overview Table 45. Pfizer Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Pfizer Solid Tumors Drugs Product Portfolio Table 47. Pfizer Recent Developments Table 48. GSK Company Information Table 49. GSK Business Overview Table 50. GSK Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. GSK Solid Tumors Drugs Product Portfolio Table 52. GSK Recent Developments Table 53. Bayer Company Information Table 54. Bayer Business Overview Table 55. Bayer Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Bayer Solid Tumors Drugs Product Portfolio Table 57. Bayer Recent Developments Table 58. AbbVie Company Information Table 59. AbbVie Business Overview Table 60. AbbVie Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. AbbVie Solid Tumors Drugs Product Portfolio Table 62. AbbVie Recent Developments Table 63. AstraZeneca Company Information Table 64. AstraZeneca Business Overview Table 65. AstraZeneca Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. AstraZeneca Solid Tumors Drugs Product Portfolio Table 67. AstraZeneca Recent Developments Table 68. Hoffmann-La Roche Company Information Table 69. Hoffmann-La Roche Business Overview Table 70. Hoffmann-La Roche Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Hoffmann-La Roche Solid Tumors Drugs Product Portfolio Table 72. Hoffmann-La Roche Recent Developments Table 73. Daiichi Sankyo Company Information Table 74. Daiichi Sankyo Business Overview Table 75. Daiichi Sankyo Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Daiichi Sankyo Solid Tumors Drugs Product Portfolio Table 77. Daiichi Sankyo Recent Developments Table 78. Celgene Company Information Table 79. Celgene Business Overview Table 80. Celgene Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Celgene Solid Tumors Drugs Product Portfolio Table 82. Celgene Recent Developments Table 83. Boston Biomedical Company Information Table 84. Boston Biomedical Business Overview Table 85. Boston Biomedical Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Boston Biomedical Solid Tumors Drugs Product Portfolio Table 87. Boston Biomedical Recent Developments Table 88. Boehringer Ingelheim Company Information Table 89. Boehringer Ingelheim Business Overview Table 90. Boehringer Ingelheim Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Boehringer Ingelheim Solid Tumors Drugs Product Portfolio Table 92. Boehringer Ingelheim Recent Developments Table 93. BMS Company Information Table 94. BMS Business Overview Table 95. BMS Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. BMS Solid Tumors Drugs Product Portfolio Table 97. BMS Recent Developments Table 98. Biogen Company Information Table 99. Biogen Business Overview Table 100. Biogen Solid Tumors Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Biogen Solid Tumors Drugs Product Portfolio Table 102. Biogen Recent Developments Table 103. Global Solid Tumors Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 104. Global Solid Tumors Drugs Sales by Region (2021-2026) & (K Units) Table 105. Global Solid Tumors Drugs Sales Market Share by Region (2021-2026) Table 106. Global Solid Tumors Drugs Sales by Region (2027-2032) & (K Units) Table 107. Global Solid Tumors Drugs Sales Market Share by Region (2027-2032) Table 108. Global Solid Tumors Drugs Revenue by Region (2021-2026) & (US$ Million) Table 109. Global Solid Tumors Drugs Revenue Market Share by Region (2021-2026) Table 110. Global Solid Tumors Drugs Revenue by Region (2027-2032) & (US$ Million) Table 111. Global Solid Tumors Drugs Revenue Market Share by Region (2027-2032) Table 112. North America Solid Tumors Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. North America Solid Tumors Drugs Sales by Country (2021-2026) & (K Units) Table 114. North America Solid Tumors Drugs Sales by Country (2027-2032) & (K Units) Table 115. North America Solid Tumors Drugs Revenue by Country (2021-2026) & (US$ Million) Table 116. North America Solid Tumors Drugs Revenue by Country (2027-2032) & (US$ Million) Table 117. Europe Solid Tumors Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Europe Solid Tumors Drugs Sales by Country (2021-2026) & (K Units) Table 119. Europe Solid Tumors Drugs Sales by Country (2027-2032) & (K Units) Table 120. Europe Solid Tumors Drugs Revenue by Country (2021-2026) & (US$ Million) Table 121. Europe Solid Tumors Drugs Revenue by Country (2027-2032) & (US$ Million) Table 122. Asia Pacific Solid Tumors Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Asia Pacific Solid Tumors Drugs Sales by Country (2021-2026) & (K Units) Table 124. Asia Pacific Solid Tumors Drugs Sales by Country (2027-2032) & (K Units) Table 125. Asia Pacific Solid Tumors Drugs Revenue by Country (2021-2026) & (US$ Million) Table 126. Asia Pacific Solid Tumors Drugs Revenue by Country (2027-2032) & (US$ Million) Table 127. South America Solid Tumors Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. South America Solid Tumors Drugs Sales by Country (2021-2026) & (K Units) Table 129. South America Solid Tumors Drugs Sales by Country (2027-2032) & (K Units) Table 130. South America Solid Tumors Drugs Revenue by Country (2021-2026) & (US$ Million) Table 131. South America Solid Tumors Drugs Revenue by Country (2027-2032) & (US$ Million) Table 132. Middle East and Africa Solid Tumors Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Middle East and Africa Solid Tumors Drugs Sales by Country (2021-2026) & (K Units) Table 134. Middle East and Africa Solid Tumors Drugs Sales by Country (2027-2032) & (K Units) Table 135. Middle East and Africa Solid Tumors Drugs Revenue by Country (2021-2026) & (US$ Million) Table 136. Middle East and Africa Solid Tumors Drugs Revenue by Country (2027-2032) & (US$ Million) Table 137. Global Solid Tumors Drugs Sales by Type (2021-2026) & (K Units) Table 138. Global Solid Tumors Drugs Sales by Type (2027-2032) & (K Units) Table 139. Global Solid Tumors Drugs Sales Market Share by Type (2021-2026) Table 140. Global Solid Tumors Drugs Sales Market Share by Type (2027-2032) Table 141. Global Solid Tumors Drugs Revenue by Type (2021-2026) & (US$ Million) Table 142. Global Solid Tumors Drugs Revenue by Type (2027-2032) & (US$ Million) Table 143. Global Solid Tumors Drugs Revenue Market Share by Type (2021-2026) Table 144. Global Solid Tumors Drugs Revenue Market Share by Type (2027-2032) Table 145. Global Solid Tumors Drugs Price by Type (2021-2026) & (US$/Unit) Table 146. Global Solid Tumors Drugs Price by Type (2027-2032) & (US$/Unit) Table 147. Global Solid Tumors Drugs Sales by Application (2021-2026) & (K Units) Table 148. Global Solid Tumors Drugs Sales by Application (2027-2032) & (K Units) Table 149. Global Solid Tumors Drugs Sales Market Share by Application (2021-2026) Table 150. Global Solid Tumors Drugs Sales Market Share by Application (2027-2032) Table 151. Global Solid Tumors Drugs Revenue by Application (2021-2026) & (US$ Million) Table 152. Global Solid Tumors Drugs Revenue by Application (2027-2032) & (US$ Million) Table 153. Global Solid Tumors Drugs Revenue Market Share by Application (2021-2026) Table 154. Global Solid Tumors Drugs Revenue Market Share by Application (2027-2032) Table 155. Global Solid Tumors Drugs Price by Application (2021-2026) & (US$/Unit) Table 156. Global Solid Tumors Drugs Price by Application (2027-2032) & (US$/Unit) Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Solid Tumors Drugs Distributors List Table 160. Solid Tumors Drugs Customers List Table 161. Solid Tumors Drugs Industry Trends Table 162. Solid Tumors Drugs Industry Drivers Table 163. Solid Tumors Drugs Industry Restraints Table 164. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Solid Tumors Drugs Product Image Figure 5. Global Solid Tumors Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Solid Tumors Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Solid Tumors Drugs Sales (2021-2032) & (K Units) Figure 8. Global Solid Tumors Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. Small Molecules Product Image Figure 10. Biologics Product Image Figure 11. Academic and Research Institutes Product Image Figure 12. Hospitals Product Image Figure 13. Clinics Product Image Figure 14. Others Product Image Figure 15. Global Solid Tumors Drugs Revenue Share by Manufacturers in 2025 Figure 16. Global Manufacturers of Solid Tumors Drugs, Manufacturing Sites & Headquarters Figure 17. Global Top 5 and 10 Solid Tumors Drugs Players Market Share by Revenue in 2025 Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Solid Tumors Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 20. Global Solid Tumors Drugs Sales by Region in 2025 Figure 21. Global Solid Tumors Drugs Revenue by Region in 2025 Figure 22. North America Solid Tumors Drugs Market Size by Country in 2025 Figure 23. North America Solid Tumors Drugs Sales Market Share by Country (2021-2032) Figure 24. North America Solid Tumors Drugs Revenue Market Share by Country (2021-2032) Figure 25. United States Solid Tumors Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Canada Solid Tumors Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Solid Tumors Drugs Market Size by Country in 2025 Figure 28. Europe Solid Tumors Drugs Sales Market Share by Country (2021-2032) Figure 29. Europe Solid Tumors Drugs Revenue Market Share by Country (2021-2032) Figure 30. Germany Solid Tumors Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Solid Tumors Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Solid Tumors Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Solid Tumors Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Netherlands Solid Tumors Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Nordic Countries Solid Tumors Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Asia Pacific Solid Tumors Drugs Market Size by Country in 2025 Figure 37. Asia Pacific Solid Tumors Drugs Sales Market Share by Country (2021-2032) Figure 38. Asia Pacific Solid Tumors Drugs Revenue Market Share by Country (2021-2032) Figure 39. China Solid Tumors Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Japan Solid Tumors Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. South Korea Solid Tumors Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. India Solid Tumors Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Australia Solid Tumors Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. China Taiwan Solid Tumors Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Southeast Asia Solid Tumors Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Southeast Asia Solid Tumors Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South America Solid Tumors Drugs Market Size by Country in 2025 Figure 48. South America Solid Tumors Drugs Sales Market Share by Country (2021-2032) Figure 49. South America Solid Tumors Drugs Revenue Market Share by Country (2021-2032) Figure 50. Mexico Solid Tumors Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Brazil Solid Tumors Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Argentina Solid Tumors Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Middle East and Africa Solid Tumors Drugs Market Size by Country in 2025 Figure 54. Middle East and Africa Solid Tumors Drugs Sales Market Share by Country (2021-2032) Figure 55. Middle East and Africa Solid Tumors Drugs Revenue Market Share by Country (2021-2032) Figure 56. Turkey Solid Tumors Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Saudi Arabia Solid Tumors Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. UAE Solid Tumors Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Global Solid Tumors Drugs Sales Market Share by Type (2021-2032) Figure 60. Global Solid Tumors Drugs Revenue Market Share by Type (2021-2032) Figure 61. Global Solid Tumors Drugs Price (US$/Unit) by Type (2021-2032) Figure 62. Global Solid Tumors Drugs Sales Market Share by Application (2021-2032) Figure 63. Global Solid Tumors Drugs Revenue Market Share by Application (2021-2032) Figure 64. Global Solid Tumors Drugs Price (US$/Unit) by Application (2021-2032) Figure 65. Solid Tumors Drugs Value Chain Figure 66. Solid Tumors Drugs Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Solid Tumors Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Small Molecules
  • Biologics
Applications
  • Academic and Research Institutes
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck
  • Eli Lilly
  • Pfizer
  • GSK
  • Bayer
  • AbbVie
  • AstraZeneca
  • Hoffmann-La Roche
  • Daiichi Sankyo
  • Celgene
  • Boston Biomedical
  • Boehringer Ingelheim
  • BMS
  • Biogen

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Solid Tumors Drugs Market Size (2021-2032)
  4. 2.2.2 Global Solid Tumors Drugs Sales (2021-2032)
  5. 2.2.3 Global Solid Tumors Drugs Market Average Price (2021-2032)
  6. 2.3 Solid Tumors Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Small Molecules
  9. 2.3.3 Biologics
  10. 2.4 Solid Tumors Drugs by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Academic and Research Institutes
  13. 2.4.3 Hospitals
  14. 2.4.4 Clinics
  15. 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Solid Tumors Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Solid Tumors Drugs Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Solid Tumors Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Solid Tumors Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Solid Tumors Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Solid Tumors Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Solid Tumors Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Solid Tumors Drugs, Established Date
  9. 3.9 Global Solid Tumors Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Sanofi
  2. 4.1.1 Sanofi Company Information
  3. 4.1.2 Sanofi Business Overview
  4. 4.1.3 Sanofi Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Sanofi Solid Tumors Drugs Product Portfolio
  6. 4.1.5 Sanofi Recent Developments
  7. 4.2 Johnson & Johnson
  8. 4.2.1 Johnson & Johnson Company Information
  9. 4.2.2 Johnson & Johnson Business Overview
  10. 4.2.3 Johnson & Johnson Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Johnson & Johnson Solid Tumors Drugs Product Portfolio
  12. 4.2.5 Johnson & Johnson Recent Developments
  13. 4.3 Novartis
  14. 4.3.1 Novartis Company Information
  15. 4.3.2 Novartis Business Overview
  16. 4.3.3 Novartis Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Novartis Solid Tumors Drugs Product Portfolio
  18. 4.3.5 Novartis Recent Developments
  19. 4.4 Merck
  20. 4.4.1 Merck Company Information
  21. 4.4.2 Merck Business Overview
  22. 4.4.3 Merck Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Merck Solid Tumors Drugs Product Portfolio
  24. 4.4.5 Merck Recent Developments
  25. 4.5 Eli Lilly
  26. 4.5.1 Eli Lilly Company Information
  27. 4.5.2 Eli Lilly Business Overview
  28. 4.5.3 Eli Lilly Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Eli Lilly Solid Tumors Drugs Product Portfolio
  30. 4.5.5 Eli Lilly Recent Developments
  31. 4.6 Pfizer
  32. 4.6.1 Pfizer Company Information
  33. 4.6.2 Pfizer Business Overview
  34. 4.6.3 Pfizer Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Pfizer Solid Tumors Drugs Product Portfolio
  36. 4.6.5 Pfizer Recent Developments
  37. 4.7 GSK
  38. 4.7.1 GSK Company Information
  39. 4.7.2 GSK Business Overview
  40. 4.7.3 GSK Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 GSK Solid Tumors Drugs Product Portfolio
  42. 4.7.5 GSK Recent Developments
  43. 4.8 Bayer
  44. 4.8.1 Bayer Company Information
  45. 4.8.2 Bayer Business Overview
  46. 4.8.3 Bayer Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Bayer Solid Tumors Drugs Product Portfolio
  48. 4.8.5 Bayer Recent Developments
  49. 4.9 AbbVie
  50. 4.9.1 AbbVie Company Information
  51. 4.9.2 AbbVie Business Overview
  52. 4.9.3 AbbVie Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 AbbVie Solid Tumors Drugs Product Portfolio
  54. 4.9.5 AbbVie Recent Developments
  55. 4.10 AstraZeneca
  56. 4.10.1 AstraZeneca Company Information
  57. 4.10.2 AstraZeneca Business Overview
  58. 4.10.3 AstraZeneca Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 AstraZeneca Solid Tumors Drugs Product Portfolio
  60. 4.10.5 AstraZeneca Recent Developments
  61. 4.11 Hoffmann-La Roche
  62. 4.11.1 Hoffmann-La Roche Company Information
  63. 4.11.2 Hoffmann-La Roche Business Overview
  64. 4.11.3 Hoffmann-La Roche Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Hoffmann-La Roche Solid Tumors Drugs Product Portfolio
  66. 4.11.5 Hoffmann-La Roche Recent Developments
  67. 4.12 Daiichi Sankyo
  68. 4.12.1 Daiichi Sankyo Company Information
  69. 4.12.2 Daiichi Sankyo Business Overview
  70. 4.12.3 Daiichi Sankyo Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Daiichi Sankyo Solid Tumors Drugs Product Portfolio
  72. 4.12.5 Daiichi Sankyo Recent Developments
  73. 4.13 Celgene
  74. 4.13.1 Celgene Company Information
  75. 4.13.2 Celgene Business Overview
  76. 4.13.3 Celgene Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Celgene Solid Tumors Drugs Product Portfolio
  78. 4.13.5 Celgene Recent Developments
  79. 4.14 Boston Biomedical
  80. 4.14.1 Boston Biomedical Company Information
  81. 4.14.2 Boston Biomedical Business Overview
  82. 4.14.3 Boston Biomedical Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Boston Biomedical Solid Tumors Drugs Product Portfolio
  84. 4.14.5 Boston Biomedical Recent Developments
  85. 4.15 Boehringer Ingelheim
  86. 4.15.1 Boehringer Ingelheim Company Information
  87. 4.15.2 Boehringer Ingelheim Business Overview
  88. 4.15.3 Boehringer Ingelheim Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Boehringer Ingelheim Solid Tumors Drugs Product Portfolio
  90. 4.15.5 Boehringer Ingelheim Recent Developments
  91. 4.16 BMS
  92. 4.16.1 BMS Company Information
  93. 4.16.2 BMS Business Overview
  94. 4.16.3 BMS Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 BMS Solid Tumors Drugs Product Portfolio
  96. 4.16.5 BMS Recent Developments
  97. 4.17 Biogen
  98. 4.17.1 Biogen Company Information
  99. 4.17.2 Biogen Business Overview
  100. 4.17.3 Biogen Solid Tumors Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Biogen Solid Tumors Drugs Product Portfolio
  102. 4.17.5 Biogen Recent Developments
5 Global Solid Tumors Drugs Market Scenario by Region
  1. 5.1 Global Solid Tumors Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Solid Tumors Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Solid Tumors Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Solid Tumors Drugs Sales by Region: 2027-2032
  5. 5.3 Global Solid Tumors Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Solid Tumors Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Solid Tumors Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Solid Tumors Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Solid Tumors Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Solid Tumors Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Solid Tumors Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Solid Tumors Drugs Market Facts & Figures by Country
  15. 5.5.1 Europe Solid Tumors Drugs Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Solid Tumors Drugs Sales by Country (2021-2032)
  17. 5.5.3 Europe Solid Tumors Drugs Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.5.9 Nordic Countries
  24. 5.6 Asia Pacific Solid Tumors Drugs Market Facts & Figures by Country
  25. 5.6.1 Asia Pacific Solid Tumors Drugs Market Size by Country: 2021 VS 2025 VS 2032
  26. 5.6.2 Asia Pacific Solid Tumors Drugs Sales by Country (2021-2032)
  27. 5.6.3 Asia Pacific Solid Tumors Drugs Revenue by Country (2021-2032)
  28. 5.6.4 China
  29. 5.6.5 Japan
  30. 5.6.6 South Korea
  31. 5.6.7 India
  32. 5.6.8 Australia
  33. 5.6.9 China Taiwan
  34. 5.6.10 Southeast Asia
  35. 5.7 South America Solid Tumors Drugs Market Facts & Figures by Country
  36. 5.7.1 South America Solid Tumors Drugs Market Size by Country: 2021 VS 2025 VS 2032
  37. 5.7.2 South America Solid Tumors Drugs Sales by Country (2021-2032)
  38. 5.7.3 South America Solid Tumors Drugs Revenue by Country (2021-2032)
  39. 5.7.4 Mexico
  40. 5.7.5 Brazil
  41. 5.7.6 Argentina
  42. 5.8 Middle East and Africa Solid Tumors Drugs Market Facts & Figures by Country
  43. 5.8.1 Middle East and Africa Solid Tumors Drugs Market Size by Country: 2021 VS 2025 VS 2032
  44. 5.8.2 Middle East and Africa Solid Tumors Drugs Sales by Country (2021-2032)
  45. 5.8.3 Middle East and Africa Solid Tumors Drugs Revenue by Country (2021-2032)
  46. 5.8.4 Turkey
  47. 5.8.5 Saudi Arabia
  48. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Solid Tumors Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Solid Tumors Drugs Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Solid Tumors Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Solid Tumors Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Solid Tumors Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Solid Tumors Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Solid Tumors Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Solid Tumors Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Solid Tumors Drugs Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Solid Tumors Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Solid Tumors Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Solid Tumors Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Solid Tumors Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Solid Tumors Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Solid Tumors Drugs Value Chain Analysis
  2. 8.1.1 Solid Tumors Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Solid Tumors Drugs Production Mode & Process
  5. 8.2 Solid Tumors Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Solid Tumors Drugs Distributors
  8. 8.2.3 Solid Tumors Drugs Customers
9 Global Solid Tumors Drugs Analyzing Market Dynamics
  1. 9.1 Solid Tumors Drugs Industry Trends
  2. 9.2 Solid Tumors Drugs Industry Drivers
  3. 9.3 Solid Tumors Drugs Industry Opportunities and Challenges
  4. 9.4 Solid Tumors Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst